Heat Biologics (NASDAQ:HTBX) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Heat Biologics (NASDAQ:HTBXGet Rating) in a research report released on Tuesday morning. The brokerage issued a sell rating on the stock.

Heat Biologics has a 1 year low of $2.07 and a 1 year high of $10.85.

An institutional investor recently raised its position in Heat Biologics stock. Jane Street Group LLC increased its position in Heat Biologics, Inc. (NASDAQ:HTBXGet Rating) by 341.4% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 17,778 shares of the company’s stock after buying an additional 25,143 shares during the period. Jane Street Group LLC owned about 0.07% of Heat Biologics worth $54,000 at the end of the most recent quarter.

Heat Biologics Company Profile (Get Rating)

Heat Biologics, Inc, an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product.

Featured Stories

Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.